復星醫藥(02196.HK)控股股東增持計劃結束 累斥9.7億人幣增持2,793萬股H股
復星醫藥(02196.HK)公布,截至昨日(30日)收市,控股股東復星高科技增持計劃實施期限已屆滿。自去年12月1日至今年11月30日,復星高科技及其控股股東復星國際(00656.HK)累計增持公司2,793.05萬股H股,累計增持金額折合約9.67億元人民幣,累計增持股份比例約佔公司已發行股份總數的1.09%,且滾動累計增持公司股份數量未超過發行股份總數的2%。
於昨日,復星高科技及復星國際合計持有公司10.16億股股份,約佔公司已發行股份總數的39.63%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.